Argonaut Technologies, Inc. Announces Promotion

Apr 26, 2001, 01:00 ET from Argonaut Technologies, Inc.

    SAN CARLOS, Calif., April 26 /PRNewswire/ --
 Argonaut Technologies, Inc. (Nasdaq: AGNT), a leading provider of innovative
 instruments and reagents for the development of new drugs, today announced the
 appointment of David P. Binkley, Ph.D. to the office of Chairman and Chief
 Executive Officer.  Lissa A. Goldenstein has been promoted to President and
 Chief Operating Officer reporting to Dr. Binkley.
     Dr. Binkley has been appointed to the office of Chairman of the Board of
 Directors and retains the Chief Executive Officer title.  This appointment
 allows Dr. Binkley to focus on the long-term strategies and external
 communication needs of Argonaut.  Dr. Binkley joined Argonaut in December 1996
 as President and Chief Executive Officer.  With his direction and guidance,
 Argonaut has expanded its offerings from a single product solution to include
 multiple instrument platforms as well as consumables and reagent products that
 address many challenging areas of drug development.  In the past year,
 Argonaut completed a successful initial public offering and purchased Camile
 Products LLC, a privately held software company.  Dr. Binkley succeeds
 Brook H. Byers as Chairman of the Board of Directors.  Mr. Byers will remain
 on the Argonaut Board of Directors.
     "Dave has done a great job growing and positioning Argonaut for the
 future.  It is a pleasure to have him succeed me as Chairman," commented
 Mr. Byers, former Chairman of the Board of Directors.
     Dr. Binkley was previously a Vice President of Perkin Elmer Corporation.
 He received his Ph.D. in chemistry from Virginia Tech.
     Ms. Goldenstein joined Argonaut in January 1998.  In August 2000, she was
 named Sr. Vice President and Chief Business Officer with responsibility for
 worldwide sales, support and marketing.
     "Lissa has been instrumental in the growth and development of Argonaut's
 sales and marketing organization," said Dr. Binkley.  "Her strong track
 record, demonstrated leadership ability and extensive knowledge of the life
 science markets make her the ideal person to successfully lead the operational
 functions for Argonaut."
     Prior to joining Argonaut, Ms. Goldenstein was Sr. Vice President with
 Molecular Simulations where she was responsible for global sales and marketing
 for the company's molecular modeling software.  Ms. Goldenstein began her
 career at McDonnell Douglas as a sales representative for CAD/CAM technology
 and held several positions there over her 10 year tenure including serving as
 the Director of Commercial Operations.  Ms. Goldenstein holds a bachelor's
 degree in civil engineering from Pennsylvania State University and a
 California Civil Engineers License.
 
     About Argonaut Technologies
     Argonaut Technologies, Inc. is a pioneer in the development of innovative
 products that speed and simplify how chemists discover and test new chemical
 entities. Our products enable chemists to increase their productivity, reduce
 their operating costs through automation and process simplification, achieve
 faster time-to-market for new products, and cost-effectively explore the
 increasing number of drug targets available for drug development.  We provide
 solutions that are used in over 825 pharmaceutical, chemical and academic
 laboratories worldwide.  Our instruments, software and consumables for
 parallel synthesis enable chemists to perform multiple experiments under a
 variety of conditions in a fraction of the time and cost of traditional
 methods.
 
                      MAKE YOUR OPINION COUNT - Click Here
                http://tbutton.prnewswire.com/prn/11690X24253831
 
 

SOURCE Argonaut Technologies, Inc.
    SAN CARLOS, Calif., April 26 /PRNewswire/ --
 Argonaut Technologies, Inc. (Nasdaq: AGNT), a leading provider of innovative
 instruments and reagents for the development of new drugs, today announced the
 appointment of David P. Binkley, Ph.D. to the office of Chairman and Chief
 Executive Officer.  Lissa A. Goldenstein has been promoted to President and
 Chief Operating Officer reporting to Dr. Binkley.
     Dr. Binkley has been appointed to the office of Chairman of the Board of
 Directors and retains the Chief Executive Officer title.  This appointment
 allows Dr. Binkley to focus on the long-term strategies and external
 communication needs of Argonaut.  Dr. Binkley joined Argonaut in December 1996
 as President and Chief Executive Officer.  With his direction and guidance,
 Argonaut has expanded its offerings from a single product solution to include
 multiple instrument platforms as well as consumables and reagent products that
 address many challenging areas of drug development.  In the past year,
 Argonaut completed a successful initial public offering and purchased Camile
 Products LLC, a privately held software company.  Dr. Binkley succeeds
 Brook H. Byers as Chairman of the Board of Directors.  Mr. Byers will remain
 on the Argonaut Board of Directors.
     "Dave has done a great job growing and positioning Argonaut for the
 future.  It is a pleasure to have him succeed me as Chairman," commented
 Mr. Byers, former Chairman of the Board of Directors.
     Dr. Binkley was previously a Vice President of Perkin Elmer Corporation.
 He received his Ph.D. in chemistry from Virginia Tech.
     Ms. Goldenstein joined Argonaut in January 1998.  In August 2000, she was
 named Sr. Vice President and Chief Business Officer with responsibility for
 worldwide sales, support and marketing.
     "Lissa has been instrumental in the growth and development of Argonaut's
 sales and marketing organization," said Dr. Binkley.  "Her strong track
 record, demonstrated leadership ability and extensive knowledge of the life
 science markets make her the ideal person to successfully lead the operational
 functions for Argonaut."
     Prior to joining Argonaut, Ms. Goldenstein was Sr. Vice President with
 Molecular Simulations where she was responsible for global sales and marketing
 for the company's molecular modeling software.  Ms. Goldenstein began her
 career at McDonnell Douglas as a sales representative for CAD/CAM technology
 and held several positions there over her 10 year tenure including serving as
 the Director of Commercial Operations.  Ms. Goldenstein holds a bachelor's
 degree in civil engineering from Pennsylvania State University and a
 California Civil Engineers License.
 
     About Argonaut Technologies
     Argonaut Technologies, Inc. is a pioneer in the development of innovative
 products that speed and simplify how chemists discover and test new chemical
 entities. Our products enable chemists to increase their productivity, reduce
 their operating costs through automation and process simplification, achieve
 faster time-to-market for new products, and cost-effectively explore the
 increasing number of drug targets available for drug development.  We provide
 solutions that are used in over 825 pharmaceutical, chemical and academic
 laboratories worldwide.  Our instruments, software and consumables for
 parallel synthesis enable chemists to perform multiple experiments under a
 variety of conditions in a fraction of the time and cost of traditional
 methods.
 
                      MAKE YOUR OPINION COUNT - Click Here
                http://tbutton.prnewswire.com/prn/11690X24253831
 
 SOURCE  Argonaut Technologies, Inc.